Pharmaceutical Industry Issues Call for Collective Action to Address the Rising Global Burden of Chronic Disease
Non-communicable diseases (NCDs) including cancer, diabetes, cardiovascular disease, lung disease, mental health, and neurological disorders are responsible for 75% of deaths worldwide.
New research demonstrates that investing an additional 1% of GDP in public healthcare spending, where at least 40% is aimed at preventing and treating NCDs, could save close to 5 million lives each year in low- and middle-income countries (LMICs).
Ahead of the Fourth High-Level Meeting of the UN General Assembly on the prevention and control of NCDs and mental health this September, the global trade association representing the pharmaceutical industry urges collective action to reduce premature deaths from NCDs through existing cost-effective interventions.
GENEVA & NEW YORK, March 11, 2025--(BUSINESS WIRE)--Ahead of a major UN milestone, the global pharmaceutical industry has issued a "Call to Action" urging collective action across the globe to tackle the rise of non-communicable diseases (NCDs) such as cancer, diabetes, cardiovascular disease, lung disease, mental health, and neurological disorders.
NCDs account for nearly 75% of global deaths. More than 18 million of the 43 million deaths that relate to NCDs are premature, with over 80% of premature deaths taking place in low- and middle-income countries (LMICs). About 33% of the global population is living with an NCD1, up to one in two of us will get cancer in our lifetimes, and about one billion people are affected by a mental health condition.
In 2021, it was estimated that investment in NCD prevention and control would yield an annual seven-fold return in LMICs within a decade. This approach, which includes lifestyle interventions such as healthy diet and exercise as well as primary healthcare, could lead to an expected USD 230 billion economic gain by 2030.
New research carried out by Airfinity, which has been released as part of the Call to Action, and demonstrates that investing an additional 1% of GDP in public healthcare spending, where at least 40% is aimed at preventing and treating NCDs through primary health care, could save approximately 5 million lives each year in LMICs. This can be achieved through implementing existing cost-effective interventions such as cardiovascular disease management, diabetes screening, and respiratory care. The data supports growing consensus that more funding is needed to bend the curve on NCDs.
The new research has been released by IFPMA, the trade association representing the pharmaceutical industry to the United Nations, ahead of the High-Level Meeting of the UN General Assembly on the prevention and control of NCDs and mental health this September. The meeting is expected to result in a political declaration to drive action to reduce the global burden of these conditions worldwide.
Over 1,400 medicines have been approved for NCDs in the past 10 years2, which have transformed how we fight disease, and are improving the lives of hundreds of millions of people living with chronic conditions. Today, there are a further 9,600 NCD medicines at various stages of research and development3.
Despite this progress, there are still significant barriers and delays in ensuring these medicines and vaccines can reach the people who need them, and there are still NCDs for which there is not adequate treatment. To improve end-to-end access for people living with NCDs, IFPMA calls for collective action to:
Enable innovation: Foster a healthy innovation ecosystem, supported by robust IP protection, and improve awareness and uptake of medical innovation to address the global NCD and mental health burden. This should include essential and innovative NCD medicines, vaccines, diagnostics, and medical devices, supported by appropriate health service delivery models.
Mobilize investment: Commit to invest more efficiently and effectively in strengthening health systems and to have concrete and actionable financing plans for NCDs and mental health so that we can more equitably reach individuals with integrated prevention, treatment, and care.
Drive implementation: Deliver effective programs and policies to ensure equitable access to NCD prevention, treatment, and care for all. Strengthen national health systems by integrating early screening, diagnosis, vaccination, comprehensive treatment options, and rehabilitation programs that effectively reach and address the needs of people living with NCDs and mental health conditions.
Ensure accountability: Implement measures to ensure accountability and high standards across all relevant sectors of government and key health stakeholders to accurately improve and report on delivery of NCDs and mental health prevention, treatment, and care. This includes a focus on monitoring the impact of vaccination, early screening, diagnosis, and treatment programs.
A political declaration that includes these recommendations can drive a vision for 2050 forward where there are fewer premature NCD deaths, reduced health systems strains, and healthier societies everywhere.
Dr David Reddy, Director General of IFPMA, said:
"While pharmaceutical innovation has led to incredible strides in how we prevent, treat, and cure diseases like cancer, cardiovascular disease, and mental health, too many people remain unable to get the healthcare they need.
"The upcoming UN High-Level Meeting provides a real opportunity to refocus attention on how cross sectoral partnerships can help increase access to cost-effective medicines and vaccines in a way that can transform – and even save - the lives of millions of people worldwide."
Supporting the call for collective action, Dr Kimberly Green, Global Director for Primary Health Care at PATH (Secretariat for the Coalition for Access to NCD Medicines and Products), said:
"While investing in NCD prevention, diagnosis, and treatment represent public health 'best buys' and are considered cost-effective, improving accessibility of essential medicines and health products has been underrepresented in discussions ahead of the UN High-Level Meeting.
Global, multisectoral action is needed to turn the tide on NCDs and reduce catastrophic out-of-pocket health costs for people living with these conditions. Investing an additional 1% of GDP in health care, where at least 40% is directed towards preventing and treating NCDs through strengthened primary health care, could save five million lives each year in lower-and-middle-income countries—an important proof point in a growing body of evidence. The time to invest in NCDs through primary health care is now."
Notes to Editor
According to the 2021 WHO Global Health Expenditure report, infectious and parasitic diseases account for the largest share of health spending (37%), followed by non-communicable diseases (26%).
About IFPMA
IFPMA represents the innovative pharmaceutical industry at the international level, engaging in official relations with the United Nations and multilateral organizations. Our vision is to ensure that scientific progress translates into the next generation of medicines and vaccines that deliver a healthier future for people everywhere. To achieve this, we act as a trusted partner, bringing our members' expertise to champion pharmaceutical innovation, drive policy that supports the research, development, and delivery of health technologies, and create sustainable solutions that advance global health.
For more information, visit ifpma.org.
1 Estimate by IFPMA, based on global prevalence numbers and assumption of two NCDs on average per person living with an NCD2 Clarivate Cortellis platform accessed in January 20253 Clarivate Cortellis platform access in January 2025. "Drugs", as defined in the Cortellis Competitive Intelligence database, may include small molecules, biologics, drug combinations, biosimilars, salts, and new versions of existing drugs with an element of innovation, like a new formulation. Only the most advanced stage of development globally is reported for each drug (for instance, if a drug is being investigated in both Phase I and Phase III for different indications, it would only be reported once, as being in Phase III).
View source version on businesswire.com: https://www.businesswire.com/news/home/20250311683359/en/
Contacts
For further information, please contact: Elliot Dunster Executive Director, Communications+41 79 502 76 90e.dunster@ifpma.org
Micaela Neumann Manager, Communications+41 79 774 23 99m.neumann@ifpma.org
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
41 minutes ago
- Yahoo
World fertility rates in 'unprecedented decline', UN says
Namrata Nangia and her husband have been toying with the idea of having another child since their five-year-old daughter was born. But it always comes back to one question: 'Can we afford it?' She lives in Mumbai and works in pharmaceuticals, her husband works at a tyre company. But the costs of having one child are already overwhelming - school fees, the school bus, swimming lessons, even going to the GP is expensive. It was different when Namrata was growing up. "We just used to go to school, nothing extracurricular, but now you have to send your kid to swimming, you have to send them to drawing, you have to see what else they can do." According to a new report by the United Nations Population Fund (UNFPA), the UN agency for reproductive rights, Namrata's situation is becoming a global norm. The agency has taken its strongest line yet on fertility decline, warning that hundreds of millions of people are not able to have the number of children they want, citing the prohibitive cost of parenthood and the lack of a suitable partner as some of the reasons. UNFPA surveyed 14,000 people in 14 countries about their fertility intentions. One in five said they haven't had or expect they won't have their desired number of children. The countries surveyed - South Korea, Thailand, Italy, Hungary, Germany, Sweden, Brazil, Mexico, US, India, Indonesia, Morocco, South Africa, and Nigeria - account for a third of the global population. They are a mix of low, middle and high-income countries and those with low and high fertility. UNFPA surveyed young adults and those past their reproductive years. "The world has begun an unprecedented decline in fertility rates," says Dr Natalia Kanem, head of UNFPA. "Most people surveyed want two or more children. Fertility rates are falling in large part because many feel unable to create the families they want. And that is the real crisis," she says. How should countries deal with falling birth rates? Why a nation of 1.45 billion wants more children The influencers who want the world to have more babies - and say the White House is on their side "Calling this a crisis, saying it's real. That's a shift I think," says demographer Anna Rotkirch, who has researched fertility intentions in Europe and advises the Finnish government on population policy. "Overall, there's more undershooting than overshooting of fertility ideals," she says. She has studied this at length in Europe and is interested to see it reflected at a global level. She was also surprised by how many respondents over 50 (31%) said they had fewer children than they wanted. The survey, which is a pilot for research in 50 countries later this year, is limited in its scope. When it comes to age groups within countries for example, the sample sizes are too small to make conclusions. But some findings are clear. In all countries, 39% of people said financial limitations prevented them from having a child. The highest response was in Korea (58%), the lowest in Sweden (19%). In total, only 12% of people cited infertility - or difficulty conceiving - as a reason for not having the number of children they wanted to. But that figure was higher in countries including Thailand (19%), the US (16%), South Africa (15%), Nigeria (14%) and India (13%). "This is the first time that [the UN] have really gone all-out on low fertility issues," says Prof Stuart Gietel-Basten, demographer at the Hong Kong University of Science and Technology. Until recently the agency focused heavily on women who have more children than they wanted and the "unmet need" for contraception. Still, the UNFPA is urging caution in response to low fertility. "Right now, what we're seeing is a lot of rhetoric of catastrophe, either overpopulation or shrinking population, which leads to this kind of exaggerated response, and sometimes a manipulative response," says Dr Kanem. "In terms of trying to get women to have more children, or fewer." She points out that 40 years ago China, Korea, Japan, Thailand and Turkey were all worried their populations were too high. By 2015 they wanted to boost fertility. "We want to try as far as possible to avoid those countries enacting any kind of panicky policies," says Prof Gietel-Basten. "We are seeing low fertility, population ageing, population stagnation used as an excuse to implement nationalist, anti-migrant policies and gender conservative policies," he says. UNFPA found an even bigger barrier to children than finances was a lack of time. For Namrata in Mumbai that rings true. She spends at least three hours a day commuting to her office and back. When she gets home she is exhausted but wants to spend time with her daughter. Her family doesn't get much sleep. "After a working day, obviously you have that guilt, being a mom, that you're not spending enough time with your kid," she says. "So, we're just going to focus on one."
Yahoo
2 hours ago
- Yahoo
RenaissThera Achieves Discovery Milestone in Its Oral Obesity Drug Program
BENGALURU, India, June 09, 2025 (GLOBE NEWSWIRE) -- RenaissThera Private Limited ('RenaissThera'), a Bengaluru-based biotechnology company, announced a major milestone in its obesity drug discovery program targeting the glucose-dependent insulinotropic polypeptide receptor (GIPR). GIPR, an incretin receptor, is a validated target for peptide-based parenteral therapies where both stimulation and inhibition has shown efficacy in treating obesity and its co-morbidities. RenaissThera is developing novel, oral small molecules, both agonists and antagonists, as a more affordable and convenient alternative aiming to expand access for underserved populations in the global obesity market projected to reach USD 38 billion by 2032. Oral small molecules are more economical to manufacture and distribute than peptide-based obesity drugs. These molecules were designed and screened using proprietary AI and ML based platforms, followed by demonstrating in-vitro activity in cell lines and in-vivo activity to impact GIPR in mice to yield 'Hits'. RenaissThera now is advancing these Hits to the Lead optimization program to select candidates for pre-IND studies. RenaissThera is filing 'Composition of Matter' and utility patents for these oral novel small molecule GIPR modulators and continues to expand its innovation portfolio targeting GIP, GLP-1, and apelin receptors in obesity and diabetes. Its AI-powered Innovation Platform, integrating GenAI and machine learning tools, is accelerating the design and optimization of novel small molecules. 'We are grateful to our investors and collaborators for supporting us in reaching this milestone. Our team is focused on pushing candidates toward IND-readiness next year and we are in active discussions with potential pharma partners and investors interested in our obesity program,' said Meena, MD, CEO of RenaissThera. RenaissThera's progress was enabled through its collaboration with VedTechBio Research Private Limited which enabled access to its Agentic AI platform RxAgentAI and discovery expertise. 'We are very pleased with the outcomes of our collaboration with RenaissThera. This milestone further validates our platform and capabilities across key therapeutic areas including obesity, Type 2 diabetes, oncology, and inflammation,' said VedTechBio's Managing Director Sudhir Nagarajan. About RenaissThera RenaissThera is a Bengaluru-based biotech company developing affordable, AI-powered novel small-molecule therapies for high-unmet-need diseases like obesity and diabetes. Its goal is to innovate for underserved populations and expand global access to novel therapies. It leverages India's CRO ecosystem for early-stage R&D to deliver globally relevant innovation. For more information Please contact: Media: Lakshmi Ramakrishna lramakrishna@ Investor & Partnership: Ramkesh Meena bd@
Yahoo
5 hours ago
- Yahoo
Somnics Health Launches iNAP Essentials: Making Innovative OSA Therapy Accessible for $58/Month
REDWOOD CITY, Calif., June 09, 2025--(BUSINESS WIRE)--Somnics Health, a pioneer in next-generation sleep apnea solutions, announces the launch of iNAP Essentials, a breakthrough program giving patients access to iNAP Sleep Therapy for just $58/month over 24 months. This new initiative removes one of the biggest barriers to treatment—cost—and expands access to comfortable, mask-free therapy for patients with Obstructive Sleep Apnea (OSA). More than 50 million Americans suffer from OSA, yet 80% remain untreated, and many who start CPAP therapy abandon it due to discomfort. The iNAP system offers a new path forward. "The OSA treatment landscape is no longer CPAP-only. iNAP is effective, comfortable, and discreet—and now, more affordable than ever," said Olivier Lauzeral, General Manager of Somnics Health. "With iNAP Essentials, we're removing the affordability hurdle." A Smarter, Simpler Solution iNAP is an FDA-cleared, clinically validated therapy that uses gentle negative pressure to keep the airway open during sleep—without forcing air through a mask. It works by creating a light vacuum in the oral cavity, shifting soft tissues forward and preventing obstruction. Key benefits include: No mask, no noise, no forced air Compact and travel-friendly Rechargeable battery lasting up to 5 nights Patients appreciate the freedom and discretion the iNAP system offers, particularly for travel and daily life. "Adherence is one of iNAP's biggest strengths," added Lauzeral. "When therapy fits into your life instead of disrupting it, patients stay with it—and that's how we win against OSA." What's Included in iNAP Essentials For $58/month for 24 months, iNAP Essentials includes: A full iNAP Starter Kit 3 months of supplies (mouthpiece, tubing) Free nationwide shipping Personalized onboarding with a trained iNAP Sleep Coach Access to the iNAP Sleep App for tracking progress and sharing data with providers After the initial supply period, patients can purchase refills as needed from Somnics' online store—offering flexibility without hidden fees or long-term commitments. "We built this program with transparency and simplicity at its core," said Lauzeral. "It's everything you need to start treatment—nothing you don't." Addressing a Changing Market While CPAP has long dominated the OSA space, patient dissatisfaction is driving demand for alternatives like oral appliances, positional therapy, and implantable devices. Many of these, however, are costly, invasive, or hard to access. iNAP stands out as non-invasive, portable, and now financially accessible. Clinical studies show iNAP can significantly reduce AHI, with outcomes on par with CPAP—but with higher comfort and adherence. More Ways to Access iNAP For patients who prefer to own their device upfront, Somnics has partnered with Affirm® to offer interest-free installment plans. "Some patients want to purchase the device outright. With Affirm, they can do that without financial strain," said Lauzeral. Provider-Guided, Patient-Focused iNAP is available by prescription only, ensuring medical oversight from a sleep specialist. Adoption is growing across VA hospitals, sleep centers, and DME providers. "Physicians are seeing the value of iNAP in improving adherence and patient satisfaction," Lauzeral emphasized. "When patients feel empowered, they stay engaged—and that's the future of sleep medicine." Advancing Health Equity Untreated sleep apnea increases the risk of heart disease, stroke, diabetes, and cognitive decline. Somnics Health sees iNAP Essentials not just as a product offering—but as a public health solution. "This isn't just about access—it's about fairness," said Lauzeral. "Sleep apnea is a serious condition, and we believe everyone deserves a shot at better health." About Somnics Health Somnics Health is a medical device company focused on advancing patient-centric solutions for sleep-disordered breathing. Its flagship product, iNAP Sleep Therapy, helps patients treat OSA without the discomfort of traditional therapies. With offices in California and Taiwan, Somnics continues to lead in innovation, education, and patient adherence. Learn More: View source version on Contacts Press Contact: Olivier Lauzeral – olivier@ Follow us on: LinkedIn | Facebook | YouTube Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
